Hypoxia-inducible factor-1-regulated protein expression and oligodendroglioma patient outcome: Comparison with established biomarkers and preoperative UCSF low-grade scoring system

Journal of Neuro-Oncology

Volumn 108, Issue 3, 2012, Pages 459-468

  Abraham, Shirley ^a   Hu, Nan ^a,b   Jensen, Randy ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

1p19q; Hypoxia; Isocitrate dehydrogensase; Molecular markers; Oligodendrogliomas; Outcomes; Progression; Survival

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE 1; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CELL PROLIFERATION; CHROMOSOME 1P; CHROMOSOME DELETION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE EVALUATION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REGULATORY MECHANISM; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; OLIGODENDROGLIOMA; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84864065015     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0839-y     Document Type: Article

References (41)

1. Chin HW, Hazel JJ, Kim TH, Webster JH (1980) Oligodendro-gliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer 45:1458-1466 (Pubitemid 10134884)
2. Engelhard HH, Stelea A, Mundt A (2003) Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 60:443-456 (Pubitemid 37323986)
3. Mork SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, Harvei S, Ganz J (1985) Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 63:881-889 (Pubitemid 16204524)
4. Reifenberger G, Kros J, Burger P, Louis D, Collins V (2000) Anaplastic oligodendroglioma. In: Kliehues P, Cavenee W (eds) Pathology and genetics of tumors of the nervous system. IARC Press, Lyon, pp 62-64
5. Packer RJ, Sutton LN, Rorke LB, Zimmerman RA, Littman P, Bruce DA, Schut L (1985) Oligodendroglioma of the posterior fossa in childhood. Cancer 56:195-199 (Pubitemid 15022871)
6. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA, Edwards BK (2011) Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103:714-736
7. Maiuri F, Del Basso De Caro ML, Iaconetta G, Peca C, Esposito M, de Divitiis E (2006) Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas. Zentralbl Neurochir 67:204-209 (Pubitemid 44951682)
8. Sepulveda Sanchez JM, Martinez Montero JC, Diez-Lobato R, Hernandez-Lain A, Cabello A, Ramos A, Gonzalez Leon P, Ri-coy Campo JR (2009) Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival\-clinical, radiological and pathologic long-term follow-up analysis. Clin Neuropathol 28:11-20
9. Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Town-send JJ, Davis R, Sawaya R, Kyritsis AP (2003) Anaplastic oli-godendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65:259-266 (Pubitemid 37505834)
10. Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M (2008) Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice. Rev Neurol (Paris) 164:595-604 (Pubitemid 351893105)
11. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY, Jensen RL (2008) Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer 113:1032-1042
12. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rossler K, Prodinger A, Budka H, Hainfellner JA (2001) Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92:165-171 (Pubitemid 32623053)
13. Birner P, Preusser M, Gelpi E, Berger J, Gatterbauer B, Ambros IM, Ambros PF, Acker T, Plate KH, Harris AL, Hainfellner JA (2004) Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and thera-peutic implications. Clin Cancer Res 10:6567-6571 (Pubitemid 39346552)
14. Jarvela S, Parkkila S, Bragge H, Kahkonen M, Parkkila AK, Soini Y, Pastorekova S, Pastorek J, Haapasalo H (2008) Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer 8:1
15. Maiuri F, Del Basso De Caro M, Siciliano A, Peca C, Vergara P, Mariniello G, Pettinato G (2010) Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and sur-vival. Clin Neuropathol 29:109-114
16. Stockhammer F, von Deimling A, Synowitz M, Blechschmidt C, van Landeghem FK (2008) Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. J Mol Histol 39: 553-560
17. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL (2007) Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res 13:2441-2448 (Pubitemid 46698595)
18. Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, Carrabba G, Mukhopadhyay D, Kim W, Liau LM, Chang SM, Smith JS, Berger MS, McDermott MW (2009) Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg 111:203-210
19. Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, McDermott MM (2008) Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 109:817-824
20. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ac-kermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245-254
21. Bullard DE, Rawlings CE 3rd, Phillips B, Cox EB, Schold SC Jr, Burger P, Halperin EC (1987) Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 60:2179-2188 (Pubitemid 17153480)
22. Dehghani F, Schachenmayr W, Laun A, Korf HW (1998) Prog-nostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol 95:493-504
23. Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW (1986) A clinicopathological study of 323 patients with oligo-dendrogliomas. Ann Neurol 19:15-21 (Pubitemid 16137974)
24. Olson JD, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442-1448 (Pubitemid 30210463)
25. Freeman L, Feigin I (1963) Oligodendroglioma with 35-year survival. J Neurosurg 20:363-365
26. Roberts M, German WJ (1969) Oligodendroglioma: a 40-year survival. Case report. J Neurosurg 31:355-357
27. Solitare GB, Robinson F, Lamarche JB (1967) Oligodendrogli-oma: recurrence following an exceptionally long postoperative symptom-free interval. Can Med Assoc J 97:862-865
28. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldan GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS (2011) International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 13:649-659
29. Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wessel-ing P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ (2009) Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro Oncol 11:737-746
30. Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Higuchi Y, Saeki N (2011) Favorable long-term outcome of low-grade oli-godendrogliomas irrespective of 1p/19q status when treated without radiotherapy. J Neurooncol 102:443-449
31. Desestret V, Ciccarino P, Ducray F, Criniere E, Boisselier B, Labussiere M, Polivka M, Idbaih A, Kaloshi G, von Deimling A, Hoang-Xuan K, Delattre JY, Mokhtari K, Sanson M (2011) Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol 105:219-224
32. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560-1566
33. Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D (2011) IDH1 and IDH2 mutations, immunohisto-chemistry and associations in a series of brain tumors. J Neu-rooncol 105:345-357
34. Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Lo-undou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719-729
35. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is animportant prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154
36. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
37. Van Den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597-1604
38. Labussiere M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, Paris S, Laffaire J, Carpentier C, Criniere E, Ducray F, El Hallani S, Mokhtari K, Hoang-Xuan K, Delattre JY, Sanson M (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74:1886-1890
39. Kaelin WG, Jr. (2011) Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol (in press)
40. Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, de Paula AM, Colavolpe C, Fuentes S, Dufour H, Barrie M, Chinot O, Ouafik L, Figarella-Branger D (2011) IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol 105:591-600
41. Williams SC, Karajannis MA, Chiriboga L, Golfinos JG, von Deimling A, Zagzag D (2011) R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma. Acta Neuropathol 121:279-281